Page last updated: 2024-10-18

histamine and Narcolepsy

histamine has been researched along with Narcolepsy in 26 studies

Narcolepsy: A condition characterized by recurrent episodes of daytime somnolence and lapses in consciousness (microsomnias) that may be associated with automatic behaviors and AMNESIA. CATAPLEXY; SLEEP PARALYSIS, and hypnagogic HALLUCINATIONS frequently accompany narcolepsy. The pathophysiology of this disorder includes sleep-onset rapid eye movement (REM) sleep, which normally follows stage III or IV sleep. (From Neurology 1998 Feb;50(2 Suppl 1):S2-S7)

Research Excerpts

ExcerptRelevanceReference
"An increased number of histaminergic neurons, identified by labeling histidine-decarboxylase (HDC) its synthesis enzyme, was unexpectedly found in patients with narcolepsy type 1 (NT1)."8.12Histamine in murine narcolepsy: What do genetic and immune models tell us? ( Dauvilliers, Y; Liblau, R; Melzi, S; Morel, AL; Peyron, C; Scoté-Blachon, C, 2022)
"To determine whether histamine cells are altered in human narcolepsy with cataplexy and in animal models of this disease."7.79Greatly increased numbers of histamine cells in human narcolepsy with cataplexy. ( Cornford, M; John, J; McGregor, R; Nishino, S; Ohtsu, H; Ramanathan, L; Sakai, N; Siegel, JM; Stone, C; Thannickal, TC; Yamanaka, A, 2013)
"We counted the number of hypothalamic neurons producing orexin, melanin-concentrating hormone, and histamine in 7 narcolepsy patients and 12 control subjects using stereological techniques."7.79Increase of histaminergic tuberomammillary neurons in narcolepsy. ( Baumann, CR; Gavrilov, YV; Haybaeck, J; Mignot, E; Reddy, H; Scammell, TE; Valko, PO; Yamamoto, M, 2013)
"To examine whether cerebrospinal fluid (CSF) histamine contents are altered in human narcolepsy and whether these alterations are specific to hypocretin deficiency, as defined by low CSF hypocretin-1."7.75Decreased CSF histamine in narcolepsy with and without low CSF hypocretin-1 in comparison to healthy controls. ( Mignot, E; Nevsimalova, S; Nishino, S; Sakurai, E; Watanabe, T; Yanai, K; Yoshida, Y, 2009)
"To (1) replicate our prior result of low cerebrospinal fluid (CSF) histamine levels in human narcolepsy in a different sample population and to (2) evaluate if histamine contents are altered in other types of hypersomnia with and without hypocretin deficiency."7.75CSF histamine contents in narcolepsy, idiopathic hypersomnia and obstructive sleep apnea syndrome. ( Chiba, S; Inoue, Y; Kanbayashi, T; Kodama, T; Kondo, H; Nishino, S; Satoh, S; Shimizu, T, 2009)
"Single doses of SUVN-G3031 up to 20 mg and multiple doses up to 6 mg once daily were found to be safe and well tolerated in healthy young adults."6.94Safety, Tolerability, and Pharmacokinetics of SUVN-G3031, a Novel Histamine-3 Receptor Inverse Agonist for the Treatment of Narcolepsy, in Healthy Human Subjects Following Single and Multiple Oral Doses. ( Bhyrapuneni, G; Goyal, VK; Jetta, S; Mohammed, AR; Muddana, NR; Mudigonda, K; Nirogi, R; Palacharla, VRC; Pandey, SK; Ravula, J; Shinde, A, 2020)
"Narcolepsy is a sleep disorder characterized in humans by excessive daytime sleepiness and cataplexy."5.51Impaired histaminergic neurotransmission in children with narcolepsy type 1. ( Dauvilliers, Y; Franco, P; Guyon, A; Inocente, CO; Lin, JS; Plancoulaine, S; Raverot, V; Villanueva, C, 2019)
"In these rare patients with cataplexy without baseline hypocretin deficiency, CSF markers should be monitored over time with potential for immune therapies in early stages to try limiting hypocretin neuron loss."5.46Temporal Changes in the Cerebrospinal Fluid Level of Hypocretin-1 and Histamine in Narcolepsy. ( Barateau, L; Chenini, S; Dauvilliers, Y; Evangelista, E; Jaussent, I; Lopez, R; Robert, P, 2017)
"Sleep attacks fragmenting wakefulness, cataplexy, excess rapid-eye-movement sleep (R) during the activity period, and enhanced increase of arterial pressure during R, which are hallmarks of narcolepsy in mice, did not occur in HDC-KO, whereas they were observed in DM mice."5.42Histamine Transmission Modulates the Phenotype of Murine Narcolepsy Caused by Orexin Neuron Deficiency. ( Bastianini, S; Berteotti, C; Cohen, G; Lin, JS; Lo Martire, V; Ohtsu, H; Silvani, A; Zoccoli, G, 2015)
"L-Histidine was administered to three patients with intractable narcolepsy (20 g/day for 2 weeks), to 4 normal volunteers (32."5.04L-Histidine: failure to affect the sleep-waking cycle in man. ( Fram, DH; Gillin, JC; Henkin, RI; Snyder, F; Wyatt, RJ, 1975)
"An increased number of histaminergic neurons, identified by labeling histidine-decarboxylase (HDC) its synthesis enzyme, was unexpectedly found in patients with narcolepsy type 1 (NT1)."4.12Histamine in murine narcolepsy: What do genetic and immune models tell us? ( Dauvilliers, Y; Liblau, R; Melzi, S; Morel, AL; Peyron, C; Scoté-Blachon, C, 2022)
"To determine whether histamine cells are altered in human narcolepsy with cataplexy and in animal models of this disease."3.79Greatly increased numbers of histamine cells in human narcolepsy with cataplexy. ( Cornford, M; John, J; McGregor, R; Nishino, S; Ohtsu, H; Ramanathan, L; Sakai, N; Siegel, JM; Stone, C; Thannickal, TC; Yamanaka, A, 2013)
"We counted the number of hypothalamic neurons producing orexin, melanin-concentrating hormone, and histamine in 7 narcolepsy patients and 12 control subjects using stereological techniques."3.79Increase of histaminergic tuberomammillary neurons in narcolepsy. ( Baumann, CR; Gavrilov, YV; Haybaeck, J; Mignot, E; Reddy, H; Scammell, TE; Valko, PO; Yamamoto, M, 2013)
"CSF histamine and tele-methylhistamine did not significantly differ between patients with narcolepsy-cataplexy and other etiologies of non-hypocretin-1 deficient central hypersomnias; these measurements, therefore, are not useful in assessing the etiology or severity of centrally mediated hypersomnia."3.78Normal cerebrospinal fluid histamine and tele-methylhistamine levels in hypersomnia conditions. ( Bayard, S; Croyal, M; Dauvilliers, Y; Delallée, N; Jaussent, I; Robert, P; Scholz, S; Schwartz, JC, 2012)
"To examine whether cerebrospinal fluid (CSF) histamine contents are altered in human narcolepsy and whether these alterations are specific to hypocretin deficiency, as defined by low CSF hypocretin-1."3.75Decreased CSF histamine in narcolepsy with and without low CSF hypocretin-1 in comparison to healthy controls. ( Mignot, E; Nevsimalova, S; Nishino, S; Sakurai, E; Watanabe, T; Yanai, K; Yoshida, Y, 2009)
"To (1) replicate our prior result of low cerebrospinal fluid (CSF) histamine levels in human narcolepsy in a different sample population and to (2) evaluate if histamine contents are altered in other types of hypersomnia with and without hypocretin deficiency."3.75CSF histamine contents in narcolepsy, idiopathic hypersomnia and obstructive sleep apnea syndrome. ( Chiba, S; Inoue, Y; Kanbayashi, T; Kodama, T; Kondo, H; Nishino, S; Satoh, S; Shimizu, T, 2009)
"Single doses of SUVN-G3031 up to 20 mg and multiple doses up to 6 mg once daily were found to be safe and well tolerated in healthy young adults."2.94Safety, Tolerability, and Pharmacokinetics of SUVN-G3031, a Novel Histamine-3 Receptor Inverse Agonist for the Treatment of Narcolepsy, in Healthy Human Subjects Following Single and Multiple Oral Doses. ( Bhyrapuneni, G; Goyal, VK; Jetta, S; Mohammed, AR; Muddana, NR; Mudigonda, K; Nirogi, R; Palacharla, VRC; Pandey, SK; Ravula, J; Shinde, A, 2020)
"Histamine was first identified in the brain about 50 years ago, but only in the last few years have researchers gained an understanding of how it regulates sleep/wake behavior."2.61Histamine: neural circuits and new medications. ( Dauvilliers, Y; Franks, NP; Jackson, AC; Scammell, TE; Wisden, W, 2019)
"Narcolepsy is a sleep disorder characterized in humans by excessive daytime sleepiness and cataplexy."1.51Impaired histaminergic neurotransmission in children with narcolepsy type 1. ( Dauvilliers, Y; Franco, P; Guyon, A; Inocente, CO; Lin, JS; Plancoulaine, S; Raverot, V; Villanueva, C, 2019)
"In these rare patients with cataplexy without baseline hypocretin deficiency, CSF markers should be monitored over time with potential for immune therapies in early stages to try limiting hypocretin neuron loss."1.46Temporal Changes in the Cerebrospinal Fluid Level of Hypocretin-1 and Histamine in Narcolepsy. ( Barateau, L; Chenini, S; Dauvilliers, Y; Evangelista, E; Jaussent, I; Lopez, R; Robert, P, 2017)
"Sleep attacks fragmenting wakefulness, cataplexy, excess rapid-eye-movement sleep (R) during the activity period, and enhanced increase of arterial pressure during R, which are hallmarks of narcolepsy in mice, did not occur in HDC-KO, whereas they were observed in DM mice."1.42Histamine Transmission Modulates the Phenotype of Murine Narcolepsy Caused by Orexin Neuron Deficiency. ( Bastianini, S; Berteotti, C; Cohen, G; Lin, JS; Lo Martire, V; Ohtsu, H; Silvani, A; Zoccoli, G, 2015)

Research

Studies (26)

TimeframeStudies, this research(%)All Research%
pre-19901 (3.85)18.7374
1990's0 (0.00)18.2507
2000's6 (23.08)29.6817
2010's13 (50.00)24.3611
2020's6 (23.08)2.80

Authors

AuthorsStudies
Kimura, Y1
Takahata, K1
Shimazaki, T1
Kitamura, S1
Seki, C1
Ikoma, Y1
Ichise, M1
Kawamura, K1
Yamada, M1
Zhang, MR1
Higuchi, M1
Nishino, I1
Suhara, T1
Melzi, S1
Morel, AL1
Scoté-Blachon, C1
Liblau, R1
Dauvilliers, Y8
Peyron, C1
Shan, L2
Linssen, S1
Harteman, Z1
den Dekker, F1
Shuker, L1
Balesar, R1
Breesuwsma, N1
Anink, J1
Zhou, J1
Lammers, GJ1
Swaab, DF1
Fronczek, R1
Nirogi, R3
Mudigonda, K1
Bhyrapuneni, G3
Muddana, NR3
Shinde, A2
Goyal, VK1
Pandey, SK1
Mohammed, AR2
Ravula, J1
Jetta, S1
Palacharla, VRC2
Manoharan, A1
Shinde, AK1
Padala, NP1
Ajjala, DR1
Subramanian, R2
Benade, V1
Daripelli, S1
Kamuju, V1
Mekala, VR1
Petlu, S1
Jayarajan, P1
Badange, R1
Jasti, V1
Lopez, R1
Barateau, L1
Evangelista, E1
Chenini, S1
Robert, P4
Jaussent, I2
Franco, P1
Inocente, CO1
Guyon, A1
Villanueva, C1
Raverot, V1
Plancoulaine, S1
Lin, JS2
Scammell, TE3
Jackson, AC1
Franks, NP1
Wisden, W1
John, J1
Thannickal, TC1
McGregor, R1
Ramanathan, L1
Ohtsu, H2
Nishino, S4
Sakai, N1
Yamanaka, A1
Stone, C1
Cornford, M1
Siegel, JM2
Valko, PO1
Gavrilov, YV1
Yamamoto, M1
Reddy, H1
Haybaeck, J1
Mignot, E3
Baumann, CR2
Saper, CB1
Sundvik, M1
Panula, P1
Bastianini, S1
Silvani, A1
Berteotti, C1
Lo Martire, V1
Cohen, G1
Zoccoli, G1
Mochizuki, T1
Sakurai, E2
Nevsimalova, S1
Yoshida, Y1
Watanabe, T2
Yanai, K2
Kanbayashi, T1
Kodama, T1
Kondo, H1
Satoh, S1
Inoue, Y1
Chiba, S1
Shimizu, T1
Bassetti, CL1
Croyal, M3
Schwartz, JC3
Labeeuw, O1
Capet, M1
Sinton, CM2
Delallée, N1
Scholz, S1
Bayard, S1
Willie, JT1
Chemelli, RM1
Tokita, S1
Williams, SC1
Kisanuki, YY1
Marcus, JN1
Lee, C1
Elmquist, JK1
Kohlmeier, KA1
Leonard, CS1
Richardson, JA1
Hammer, RE1
Yanagisawa, M1
Fujiki, N1
Ripley, B1
Kato, M1
Bayer, L1
Eggermann, E1
Serafin, M1
Saint-Mleux, B1
Machard, D1
Jones, B1
Mühlethaler, M1
Gillin, JC1
Fram, DH1
Wyatt, RJ1
Henkin, RI1
Snyder, F1

Clinical Trials (4)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Clinical Study on Histamine H3 Receptor Occupancy of TS-091 by PET Examination in Healthy Adult Subjects[NCT04631276]Phase 112 participants (Actual)Interventional2014-12-11Completed
A Phase 2, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of 2 mg and 4 mg SUVN-G3031 Compared to Placebo in Patients With Narcolepsy With and Without Cataplexy[NCT04072380]Phase 2190 participants (Actual)Interventional2019-09-21Completed
A Single-center, Double-blind, Placebo-controlled, Randomized, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SUVN-G3031 After Single Ascending Doses and Multiple Ascending Doses in Healthy Male Subjects[NCT02342041]Phase 164 participants (Actual)Interventional2014-09-30Completed
A Multi-Signal Based Monitoring System for CNS Hypersomnias : A 10-year Longitudinal Study[NCT05443373]600 participants (Anticipated)Observational2020-06-04Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

4 reviews available for histamine and Narcolepsy

ArticleYear
Histamine: neural circuits and new medications.
    Sleep, 2019, 01-01, Volume: 42, Issue:1

    Topics: Animals; Cataplexy; gamma-Aminobutyric Acid; Histamine; Humans; Hypothalamic Area, Lateral; Narcolep

2019
Interactions of the orexin/hypocretin neurones and the histaminergic system.
    Acta physiologica (Oxford, England), 2015, Volume: 213, Issue:2

    Topics: Animals; Brain; Histamine; Humans; Intracellular Signaling Peptides and Proteins; Narcolepsy; Neuron

2015
Interactions of the histamine and hypocretin systems in CNS disorders.
    Nature reviews. Neurology, 2015, Volume: 11, Issue:7

    Topics: Alzheimer Disease; Animals; Histamine; Histamine Agonists; Histamine H1 Antagonists; Histamine H3 An

2015
Orexin/hypocretin plays a role in the response to physiological disequilibrium.
    Sleep medicine reviews, 2011, Volume: 15, Issue:3

    Topics: Adaptation, Physiological; Animals; Arousal; Brain; Cataplexy; Dopamine; Energy Metabolism; gamma-Am

2011

Trials

2 trials available for histamine and Narcolepsy

ArticleYear
Safety, Tolerability, and Pharmacokinetics of SUVN-G3031, a Novel Histamine-3 Receptor Inverse Agonist for the Treatment of Narcolepsy, in Healthy Human Subjects Following Single and Multiple Oral Doses.
    Clinical drug investigation, 2020, Volume: 40, Issue:7

    Topics: Administration, Oral; Adult; Cross-Over Studies; Double-Blind Method; Drug Inverse Agonism; Female;

2020
Safety, Tolerability, and Pharmacokinetics of SUVN-G3031, a Novel Histamine-3 Receptor Inverse Agonist for the Treatment of Narcolepsy, in Healthy Human Subjects Following Single and Multiple Oral Doses.
    Clinical drug investigation, 2020, Volume: 40, Issue:7

    Topics: Administration, Oral; Adult; Cross-Over Studies; Double-Blind Method; Drug Inverse Agonism; Female;

2020
Safety, Tolerability, and Pharmacokinetics of SUVN-G3031, a Novel Histamine-3 Receptor Inverse Agonist for the Treatment of Narcolepsy, in Healthy Human Subjects Following Single and Multiple Oral Doses.
    Clinical drug investigation, 2020, Volume: 40, Issue:7

    Topics: Administration, Oral; Adult; Cross-Over Studies; Double-Blind Method; Drug Inverse Agonism; Female;

2020
Safety, Tolerability, and Pharmacokinetics of SUVN-G3031, a Novel Histamine-3 Receptor Inverse Agonist for the Treatment of Narcolepsy, in Healthy Human Subjects Following Single and Multiple Oral Doses.
    Clinical drug investigation, 2020, Volume: 40, Issue:7

    Topics: Administration, Oral; Adult; Cross-Over Studies; Double-Blind Method; Drug Inverse Agonism; Female;

2020
L-Histidine: failure to affect the sleep-waking cycle in man.
    Psychopharmacologia, 1975, Volume: 40, Issue:4

    Topics: Adult; Clinical Trials as Topic; Electroencephalography; Electromyography; Electrooculography; Femal

1975

Other Studies

20 other studies available for histamine and Narcolepsy

ArticleYear
Pharmacokinetic and pharmacodynamic assessment of histamine H
    European journal of nuclear medicine and molecular imaging, 2022, Volume: 49, Issue:4

    Topics: Brain; Histamine; Humans; Ligands; Male; Narcolepsy; Neuroprotective Agents; Niacinamide; Positron-E

2022
Histamine in murine narcolepsy: What do genetic and immune models tell us?
    Brain pathology (Zurich, Switzerland), 2022, Volume: 32, Issue:2

    Topics: Animals; Histamine; Histidine Decarboxylase; Humans; Mice; Mixed Function Oxygenases; Narcolepsy; Or

2022
Activated Wake Systems in Narcolepsy Type 1.
    Annals of neurology, 2023, Volume: 94, Issue:4

    Topics: Arginine Vasopressin; Corticotropin-Releasing Hormone; Dopamine; Histamine; Humans; Narcolepsy; Nore

2023
Absorption, distribution, metabolism, excretion (ADME), drug-drug interaction potential and prediction of human pharmacokinetics of SUVN-G3031, a novel histamine 3 receptor (H
    European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2020, Sep-01, Volume: 152

    Topics: Animals; Dogs; Drug Interactions; Hepatocytes; Histamine; Humans; Microsomes, Liver; Morpholines; Na

2020
Samelisant (SUVN-G3031), a potent, selective and orally active histamine H3 receptor inverse agonist for the potential treatment of narcolepsy: pharmacological and neurochemical characterisation.
    Psychopharmacology, 2021, Volume: 238, Issue:6

    Topics: Animals; Electroencephalography; Histamine; Histamine Agonists; Humans; Male; Methylhistamines; Mice

2021
Temporal Changes in the Cerebrospinal Fluid Level of Hypocretin-1 and Histamine in Narcolepsy.
    Sleep, 2017, Jan-01, Volume: 40, Issue:1

    Topics: Adolescent; Adult; Biomarkers; Cataplexy; Child; Female; Histamine; Histocompatibility Testing; HLA-

2017
Impaired histaminergic neurotransmission in children with narcolepsy type 1.
    CNS neuroscience & therapeutics, 2019, Volume: 25, Issue:3

    Topics: Adolescent; Body Mass Index; Child; Child, Preschool; Female; Histamine; Humans; Male; Methylhistami

2019
Greatly increased numbers of histamine cells in human narcolepsy with cataplexy.
    Annals of neurology, 2013, Volume: 74, Issue:6

    Topics: Adult; Aged, 80 and over; Animals; Brain; Cataplexy; Cell Count; Disease Models, Animal; Dogs; Femal

2013
Increase of histaminergic tuberomammillary neurons in narcolepsy.
    Annals of neurology, 2013, Volume: 74, Issue:6

    Topics: Aged; Aged, 80 and over; Animals; Ataxin-3; Cell Count; Disease Models, Animal; Female; Histamine; H

2013
Restoration: potential for compensatory changes in numbers of neurons in adult human brain.
    Annals of neurology, 2013, Volume: 74, Issue:6

    Topics: Adult; Brain; Cell Count; Histamine; Humans; Intracellular Signaling Peptides and Proteins; Narcolep

2013
Histamine Transmission Modulates the Phenotype of Murine Narcolepsy Caused by Orexin Neuron Deficiency.
    PloS one, 2015, Volume: 10, Issue:10

    Topics: Animals; Body Weight; Cardiovascular System; Cataplexy; Energy Intake; Female; Gene Knockout Techniq

2015
Is low histamine a fundamental cause of sleepiness in narcolepsy and idiopathic hypersomnia?
    Sleep, 2009, Volume: 32, Issue:2

    Topics: Brain; Cataplexy; Disorders of Excessive Somnolence; Histamine; Humans; Intracellular Signaling Pept

2009
Decreased CSF histamine in narcolepsy with and without low CSF hypocretin-1 in comparison to healthy controls.
    Sleep, 2009, Volume: 32, Issue:2

    Topics: Adult; Cataplexy; Disorders of Excessive Somnolence; Female; Histamine; Humans; Intracellular Signal

2009
CSF histamine contents in narcolepsy, idiopathic hypersomnia and obstructive sleep apnea syndrome.
    Sleep, 2009, Volume: 32, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents; Cataplexy; Central Nervous System Stimulants;

2009
Cerebrospinal fluid histamine levels are decreased in patients with narcolepsy and excessive daytime sleepiness of other origin.
    Journal of sleep research, 2010, Volume: 19, Issue:4

    Topics: Adult; Aged; Disorders of Excessive Somnolence; Female; Histamine; Humans; Idiopathic Hypersomnia; M

2010
Histamine and tele-methylhistamine quantification in cerebrospinal fluid from narcoleptic subjects by liquid chromatography tandem mass spectrometry with precolumn derivatization.
    Analytical biochemistry, 2011, Feb-01, Volume: 409, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Calibration; Child; Chromatography, High Pressure Liquid

2011
Normal cerebrospinal fluid histamine and tele-methylhistamine levels in hypersomnia conditions.
    Sleep, 2012, Oct-01, Volume: 35, Issue:10

    Topics: Adult; Disorders of Excessive Somnolence; Female; Histamine; Humans; Male; Methylhistamines; Middle

2012
Distinct narcolepsy syndromes in Orexin receptor-2 and Orexin null mice: molecular genetic dissection of Non-REM and REM sleep regulatory processes.
    Neuron, 2003, Jun-05, Volume: 38, Issue:5

    Topics: Animals; Arousal; Carrier Proteins; Cells, Cultured; Clomipramine; Disease Models, Animal; Efferent

2003
Decreased brain histamine content in hypocretin/orexin receptor-2 mutated narcoleptic dogs.
    Neuroscience letters, 2001, Nov-09, Volume: 313, Issue:3

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Brain Chemistry; Cerebral Cortex; Chromatography, Hi

2001
Orexins (hypocretins) directly excite tuberomammillary neurons.
    The European journal of neuroscience, 2001, Volume: 14, Issue:9

    Topics: Action Potentials; Animals; Biotin; Carrier Proteins; Efferent Pathways; Histamine; Hypothalamic Are

2001